These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7880027)

  • 1. [Role of pharmacy professionals in the network of drug addict care. Follow-up: buprenorphine, methadone, general practitioner network].
    Gelbhart P
    Ann Med Interne (Paris); 1994 Nov; 145 Suppl 3():67-8. PubMed ID: 7880027
    [No Abstract]   [Full Text] [Related]  

  • 2. [Incidence of the development of substitution treatments and specialized care centers].
    Morel A
    Ann Med Interne (Paris); 1994 Nov; 145 Suppl 3():82-3. PubMed ID: 7880034
    [No Abstract]   [Full Text] [Related]  

  • 3. Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995-2005.
    Sheridan J; Manning V; Ridge G; Mayet S; Strang J
    Addiction; 2007 Nov; 102(11):1824-30. PubMed ID: 17935587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neonatal and maternal outcomes following maternal use of buprenorphine or methadone during pregnancy: findings of a retrospective audit.
    Blandthorn J; Forster DA; Love V
    Women Birth; 2011 Mar; 24(1):32-9. PubMed ID: 20864426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
    Fhima A; Henrion R; Lowenstein W; Charpak Y
    Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Maintenance treatment with high-dose buprenorphine: are the recommendations being followed?].
    Seyer D; Dif C; Balthazard G; Sciortino V
    Therapie; 1998; 53(4):349-54. PubMed ID: 9806004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [How would the development of substitution treatments modify the care of drug addicts?].
    Charles-Nicolas A
    Ann Med Interne (Paris); 1994 Nov; 145 Suppl 3():79-81. PubMed ID: 7880033
    [No Abstract]   [Full Text] [Related]  

  • 8. [Can the general practitioner care for outpatient drug addicts without substitution treatments? What products can he use?].
    Binder P
    Ann Med Interne (Paris); 1994 Nov; 145 Suppl 3():62-4. PubMed ID: 7880025
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacotherapeutic environments for substance use disorders.
    Gardner TJ; Kosten TR
    Am J Drug Alcohol Abuse; 2007; 33(5):627-9. PubMed ID: 17891655
    [No Abstract]   [Full Text] [Related]  

  • 10. [Value and limitations of substitution treatments in the care of drug addicts].
    Carpentier J; Bloch-Lainé JF; Hefez S
    Ann Med Interne (Paris); 1994 Nov; 145 Suppl 3():50-1. PubMed ID: 7880019
    [No Abstract]   [Full Text] [Related]  

  • 11. [Management of drug addiction in France (a short history)].
    Chossegros P
    Gastroenterol Clin Biol; 2007; 31(8-9 Pt 3):4S44-50. PubMed ID: 17965635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients.
    Maremmani I; Pani PP; Pacini M; Perugi G
    J Subst Abuse Treat; 2007 Jul; 33(1):91-8. PubMed ID: 17588494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine replacement therapy: a confirmed benefit.
    Prescrire Int; 2006 Apr; 15(82):64-70. PubMed ID: 16604748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Substitution treatments. Pharmacological and legislative aspects].
    Bouchez J; Khan-Shaghaghi E; Beauverie P; Poisson N
    Soins; 1997; (612):7-10. PubMed ID: 9110879
    [No Abstract]   [Full Text] [Related]  

  • 16. [Maintenance treatment for opioid dependence in care centers: the OPPIDUM program of the Evaluation and Information Centers for Drug Addiction].
    Thirion X; Barrau K; Micallef J; Haramburu F; Lowenstein W; Sanmarco JL
    Ann Med Interne (Paris); 2000 Apr; 151 Suppl A():A10-7. PubMed ID: 10855372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex)].
    Duburcq A; Charpak Y; Blin P; Madec L
    Rev Epidemiol Sante Publique; 2000 Aug; 48(4):363-73. PubMed ID: 11011303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Maintenance treatment for opiate dependence. Which should we deliver and how should we prescribe it?].
    Jacquiez O
    Ann Med Interne (Paris); 2003 Jun; 154 Spec No 1():S55-7. PubMed ID: 12910035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences between general practitioner- and addiction centre-prescribed buprenorphine substitution therapy in France. Preliminary results.
    Vignau J; Brunelle E
    Eur Addict Res; 1998; 4 Suppl 1():24-8. PubMed ID: 9767203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified.
    Nielsen S; Dietze P; Dunlop A; Muhleisen P; Lee N; Taylor D
    Drug Alcohol Rev; 2007 Mar; 26(2):143-51. PubMed ID: 17364849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.